immatics has a solid financial basis, with leading international life science investors supporting its business. 

Through its series A financing round in 2004/2005, immatics raised more than € 14 million from top tier venture capital firms.

In February 2007, in addition to the existing consortium, Dietmar Hopp as the new lead investor together with new co-investors, committed additional € 40 million to support the success story of immatics.

A series C financing round of €54 million was raised in September 2010 with approximately half of the investment coming from new investors MIG AG and AT Impf GmbH.

AT Impf GmbH

Dievini Hopp BioTech Holding GmbH & Co.KG

-/ www.dievini.com

EMBL Ventures
-/ www.embl-ventures.com

Grazia Equity
-/ www.grazia-equity.com

KfW Anstalt des öffentlichen Rechts
-/ www.kfw.de

L-EA
-/ www.l-ea.de

MIG AG
-/ www.mig.ag

Merifin Capital
-/ www.merifin.com

National Technology Enterprises Company
-/ www.ntec.com.kw 

Vinci Capital/Renaissance
-/ www.vincicapital.ch
-/ www.renaissance-pme.ch

Wellington Partners
-/ www.wellington-partners.com